Clinical Trial

Lutathera and ASTX727 in Neuroendocrine Tumours

Study acronym: LANTana
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use \[68Ga\]-DOTA-TATE PET to image epigenetic modification of the receptor locus.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-12-16; most recent amendment 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2022-07-14
Trial Details
NCT Number NCT05178693
Lead Sponsor Imperial College London
Collaborators: Advanced Accelerator Applications
Conditions Neuroendocrine Tumors
Enrollment 27 participants
Start Date 2022-04-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-24